updat canada roll-out fda submiss
make blood-bas screen nu realiti
strong finish year outreach
look arvo increment updat
review polari recruit pick steam pt
updat anticip data point
first public skint build base commerci adopt
report may approv week time
report look mid-year catalyst
confid top-line pipelin poc
analyst certif import disclosur see
updat proof slurri
leadership chang signal plan track
review focus year clinic execut
thought ahead rocklatan pdufa
rapid progress protect first-mov advantag look aacr
import updat
andiamo anchiano initi outperform
fda unlik take action manufactur facil statu
updat focus mileston
review momentum build eha pt
updat canada roll-out fda submiss
yesterday hsdt report provid commerci updat roll-out pon devic canada fda submiss
canada patient treatment underway two center three addit center target head year hsdt
conserv guid revenu open two center guidanc still ahead think us hsdt respond
fda answer addit question receiv januari remind point estim assum us revenu
hsdt clinic experi program cep us underway design build relationship lead neurorehabilit
center current five collect addit data reimburs open-label clinic studi
make blood-bas screen nu realiti
thursday volitionrx report result provid busi updat compani show tangibl sign progress transit
product-grad nu assay earli result suggest new protocol reagent optim robust capabl deliv impress
diagnost power small-scal studi could support commerci result recapitul larger valid trial optim
effort continu believ compani remain track final panel diagnost assay eu colorect cancer
screen end separ volitionrx report encourag earli proof-of-concept data nu assay lung cancer result
on-going trial preval cancer anticip could inform develop plan
year american academi orthoped surgeon aao robot surprisingli took center stage highlight first mover
advantag mako build data set around system benefit made impress show thought first rosa
showcas particularli soft-tissu balanc softwar snn highlight navio system next-gener platform
smaller footprint indic target launch orthotaxi robot system late focu digit surgeri
orthoped compani highlight need prepar increas move procedur ambulatori surgeri center asc
move still expect gradual sever compani note implant price meaning differ today asc versu
hospit compani market observ
top stori administr issu budget would implement total cut includ signific cut healthcar
lower payment hh epa state depart budget request call draconian cut hh
fund mandatori cut health program total includ hundr billion medicar furthermor bill make
dramat chang medicaid includ impos mandatori work requir also would repeal favor republican-
support repeal/replac legisl howev propos view even start point negoti congress given
democrat control hous
strong finish year outreach
report strong end year revenu quarter outreach pool end year outreach
pool alreadi reach strong indic traction health plan expans aetna
expand compani note reach state current expans new debt provid capit
invest work capit need appeas investor potenti equiti dilut growth outreach
pool make us believ strong revenu growth increas confid estim increas
year reiter outperform
suppli chain improv de-risk opregen develop look arvo increment updat
report financi result provid updat opregen includ expect number cohort patient
present arvo three patient revis studi protocol incorpor commerci viabl suppli chain new inject
devic plan complet enrol opregen studi end prior expect mid-year view move
thaw-and-inject distribut process use next-gener inject devic sub-retin deliveri import decis new
manag de-risk futur regulatori studi commerci howev implement chang push expect timelin
opregen launch reduc pt
review polari recruit pick steam pt
catabasi catb report earn provid investor updat recruit on-going pivot phase polarisdmd
clinic trial continu apac catb expect conclud recruit top-lin readout encourag
speed site initi patient recruit speak strong phase data movedmd studi compani continu
interact fda regard potenti acceler approv file still expect meet occur next month last
catb report encourag long-term data edasanolex movedmd lead us reconsid price model drug
us adjust pt share dilut recent rais stay bullish
updat anticip data point
report financi result pipelin updat ep line estim
consensu develop program track data oral carbapenem show safety/toler
dose advanc singl pivot current start-up phase pk/pd data data tox data
posit sad/mad data priorit decis happen year grant qualifi
infecti diseas product qidp design fda current evalu trial data
cash balanc plu barda contract fund oper accord manag
first public skint build base commerci adopt
case studi skint publish intern wound journal data newth case present diabet
foot global confer oct first time data skint present peer-review journal believ
public expand awar skint surgeon provid framework separ reimburs coverag skint
outpati set address potenti clinic data overhang investor expect compani present financi
result next week
report may approv week time
net loss vs revenu vs pdufa date proprietari hyperimmun globulin
timelin bivigam nebul fda still assign action date despit earli januari pa re-submiss
conserv assum six month review period nonetheless per management compani agenc continu interact construct
bivigam although similar materi submit connect review expect impact time
decis optimist posit fda action view trigger share out-performance
fda approv rocklatan updat model reflect manag guidanc revenu cash burn lower
revenu line compani commentari regard potenti variabl wholesal order pattern
impact rocklatan launch may revenu estim remain full-year revenu vs
maintain outperform rate price target
specialti
report look mid-year catalyst
net loss vs top-lin data second pivot trial iv tramadol post-op pain expect
optimist success anticip approv trigger acquisit invagenat exist
agreement reiter outperform rate
tuesday aptos report earn provid busi updat first aml patient dose on-going phase trial
encourag earli evid support drug moa especi consid low start dose expect
compani clinic stage pipelin expand slate enter first-in-human trial ind dual inhibitor file
februari compani plan hit ground run multipl site on-line end april earli data trial potenti
docket later year think aptos microcap stori deserv investor radar reiter outperform pt
exit vast major sales/earn review focu updat week undertook brief review
expect come one three month cover name came away bit surpris high expect bake
bloomberg consensu estim see exhibit univers look potenti beat mute expect
among smid name snss arql catb potenti materi catalyst approach would
cautiou specif small/mid-cap name broadli expect end high asid
near-term concern still bullish biotechnolog space
confid top-line pipelin poc
announc posit interim result studi congenit adren hyperplasia ad import new asset
pipelin studi establish proof concept poc oral receptor antagonist treatment adult
plan meet fda design adult pivot studi initi indic suffici preclin toxicolog work initi
poc studi pediatr believ posit studi restor investor confid capabl follow
disappoint ts result ingrezza separ manag describ top-line runway sever growth year ingrezza td base
larg gap diagnosi preval rate rais pt detail insid
updat proof slurri
tuesday report result review recent progress manag reiter plan present top-line result on-going
phase trial mid-year could establish poc patient hyperammonemia phenylketonuria
pku respect trial util bacteri slurri formul manag indic futur trial would use pill-bas formul
transit may requir clinic bridg studi view new formul essenti commerci viabil
demonstr meaning impact serum ammonia next step could includ trial urea cycl disord ucd indic
establish biomarker-bas registr endpoint cash believ adequ resourc sustain oper
reiter outperform pt
leadership chang signal plan track
spoke manag leadership transit believ compani well posit understand gal cohen made
decis resign mdwd year plan pursu opportumn mr cohen indic mdwd
achiev key goal detect studi complet met endpoint nexobrid still track bla submiss
previous disclos strateg process still on-going led steve will becom activ chairman indic
strateg process progress toward complet like year-end view sharon malka well qualifi becom ceo serv
year mdwd cfo
review focus year clinic execut
cellecti cll report sales/earn focus call clinic updat toward year-end cll
indic vari level clinic data would present three proprietari project potenti
sinc cll dose escal phase data depend function dose escal
non-linear clinic trial believ uniqu cll allogen technolog manifest technolog challeng gene
edit manufactur scale-up issu compani abl address also believ cll abl address
uniqu challeng allogen car-t possess clinic drug develop updat estim results/guid stay bullish
ralli vs nbi data two recent in-licens product candid axo-lenti-pd deliv three
enzym produc gene aadc th prosavin reorder optim dopamin product data initi lowest dose
tu therapi well toler patient data suggest great initi activ vs prosavin averag updr part score
improv point month point patient axo-lenti-pd show benefit multipl measur dyskinesia
updr compon second cohort dose tu well toler one patient
advanc infantil tay-sach diseas increas csf -hexosaminidas enzym activ meaning
thought ahead rocklatan pdufa
favor bias toward upcom fda action rocklatan pdufa base attract clinic profil rel
intraocular pressur iop manag therapi recal outperform thesi driven us market potenti rocklatan
once-daili fixed-dos combin rhopressa first-in-class inhibitor latanoprost solid rhopressa commerci execut
manag believ rocklatan may launch among prescrib univers alreadi familiar use rocki manag
iop patient open-angl glaucoma ocular hypertens oht model rocklatan launch revenu
await time approv estim impact pt six-month delay impact delay
strongbridg report updat long-term phase sonic data data provid earli setup upcom logic readout
remain focus compani interact fda expect quarter updat pleas overal
safeti profil report alt/st elev uln sever liver-rel note eros patient
number patient complet extens studi patient enter stay bullish
monday sere announc multi-year research collabor astrazeneca investig microbiome-target therapi improv
efficaci immuno-oncolog i/o drug per agreement astrazeneca pay sere span three year reimburs
research-rel expens exchang right first refus program aris collabor astrazenca agreement
mark second clinic collabor sere larg biopharma compani believ astrazeneca interest support
mount evid suggest gut microbiom dramat influenc respons blockad compani recent
initi phase trial investig sere donor-deriv ecobiot combin nivolumab melanoma patient reiter
outperform pt
rapid progress protect first-mov advantag look import updat
ntgn report unev financi result reiter plan present top-lin data studi
updat timelin commun data studi cta importantli believ ntgn success
protect first-mov advantag person neoantigen product develop oral present relationship
immun respons clinic outcom data ten melanoma patient also plan present first long-term follow-up
larg neoantigen studi potenti
last week includ acquisit updat client passport amzn-jpm-berkshir health jv name
focu improv care access navig system lower cost treatment drug invest beth israel studi
ai boost schedul effici bloomberg meanwhil eric topol said ai healthcar best pattern speech scan
wsj onc februari inform block propos weigh public hospital-insur negoti rate wsj gag claus
keep doc discuss error hinder interoper said wsj vendor urg onc extend inform
block comment period past fierc hcit fda chief gottlieb resign famili reason final cmss verma said stark
law chang vbp biggest updat ever allow referr mhn
andiamo anchiano initi outperform
initi coverag ancn outperform rate price target ancn commit expand treatment option
non-muscl invas bladder cancer nmibc develop inodiftagen target biotherapeut on-going trial
treatment-refractori set could provid short path sale opportun us alon relev clinic data coupl
modest regulatori bar fuel optim success plan evalu inodiftagen earlier-lin therapi could meaning expand
commerci potenti believ upcom interim reveal potenti registr trial captur investor attent
fda unlik take action manufactur facil statu appear secur outperform pt
base updat classif post fda websit believ manufactur inspect review may close near-term
review statu skint unlik expect regulatori chang lift major overhang share would buyer
strength specif fda chang classif inspect describ eight manufactur defici voluntari
action indic vai vai mean fda intend take regulatori action see vai definit view strength stock late
last week potenti attribut chang inspect statu believ inform wide dissemin market
view implic regard statu appreci investor
updat focus mileston
cnat announc net revenu vs consensu ep decemb cnat top-lin result
encore-ph trial patient compens earli decompens nash cirrhosi ph meet primari endpoint
decreas mean hvpg vs placebo howev compens nash cirrhosi patient post hoc analys demonstr consist
improv design cnat wait result on-going encore-nf nf nash design
best-suit pivot program addit cnat announc inhibitor inflammasom pathway enter
clinic cnat suffici fund ye cash balanc complet on-going trial project cash balanc exclud
mileston
review momentum build eha pt
sunesi snss report gave corpor updat auspici updat came posit updat revers btk
inhibitor develop peer arql rate op underscor potenti opportun non-coval bound btk-inhibit snss updat
encouragingli frame clinic object center around key clinic updat european hematolog associ eha
meet june compani enrol evalu patient first therapeut dose level bid anticip
june updat thought clinic depth clariti keep eye safeti stay bullish name
 annual healthcar confer westin grand hotel new york -- next tuesday wednesday
jun spark institut biotech summit stanford univers menlo park ca
healthcar provid manag
